5 oktober 2023: Zie ook dit artikel in gerelateerde artikelen: https://kanker-actueel.nl/groene-thee-en-in-het-bijzonder-egcg-in-relatie-tot-gezondheid-en-ziekte-waaronder-kanker-een-review-van-arts-bioloog-drs-engelbert-valstar-aan-de-hand-van-de-literatuur.html

5 oktober 2023: Bron: BMC Gastroenterology volume 23, Article number: 294 (2023)

Uit een meta-analyse van totaal 239 studies uitgevoerd door Yu Huang van het Department of Biomedical Sciences, City University of Hong Kong blijkt het dagelijks drinken van enkele koppen thee en dan vooral groene thee het risico op het ontwikkelen van vormen van darmkanker met 24 procent te verminderen. Maar zeggen ook de auteurs dit percentage is ook onzeker omdat het werkelijke effect op het risico kan variëren van een reductie van 51% tot een toename van 18%, maar regionale en bevolkingsverschillen kunnen deze verschillen hebben veroorzaakt.
Wel geeft groene thee een substantiële vermindering van het risico over alle studies gemeten.
Bij zwarte thee verschilden echter de studieresultaten zo sterk dat er geen eenduidige conclusie is te trekken, aldus de auteurs van een meta-analyse.

Ik ga hier niet verder in op details omdat het volledige studierapport gratis is te lezen of te downloaden en daar staat heel veel gedetailleerde informatie met grafieken en refentielijst. Dus kunt u zelf een en ander opzoeken.

Achtereenvolgens abstract van de meta-analyse en abstract van een gerandomiseerde studie met groene thee extract en kwaadaardige darmpoliepen (adenomen):

Association between tea consumption and colorectal cancer: a systematic review and meta-analysis of a population-based study

BMC Gastroenterology volume 23, Article number: 294 (2023) Cite this article

 

Abstract

Purpose

A meta-analysis study was performed to systematically assess the association between tea consumption and CRC risk.

Methods

Cochrane Library, Embase, PubMed, and Web of Science were retrieved to collect articles in English since 24 July 2023. Databases were searched and evaluated by two reviewers independently.We screened the literature based on inclusion and exclusion criteria. After determining the random effect model or fixed utility model based on a heterogeneity test, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated.

Results

We included fourteen articles in this meta-analysis. We analyzed the data using a random effect model to explore the association between tea consumption and CRC because of apparent heterogeneity (P < 0.001, I2 = 99.5%). The combined results of all tests showed that there is no statistically significant association between tea consumption and CRC risk (OR = 0.756, 95%CI = 0.470–1.215, P = 0.247). Subsequently, subgroup analysis and sensitivity analysis were performed. Excluding any single study, the overall results ranged from 0.73 (95%CI = 0.44–1.20) to 0.86 (95%CI = 0.53–1.40). It was determined that there was no significant publication bias between tea consumption and CRC risk (P = 0.064) by Egger's tests.

Conclusions

The results indicated that tea consumption may not be significantly associated with the development of CRC.

Implications of key findings

Tea reduces colon cancer risk by 24%, but the estimate is uncertain. The actual effect on risk can range from a reduction of 51% to an increase of 18%, but regional and population differences may cause differences.

epigallocatechingallate (EGCG) was well tolerated, but there was no statistically significant difference in the adenoma rate between the GTE group and the placebo groups in the whole study population

Abstract

Introduction: Preclinical, epidemiological, and small clinical studies suggest that green tea extract (GTE) and its major active component epigallocatechingallate (EGCG) exhibit antineoplastic effects in the colorectum.

Methods: A randomized, double-blind trial of GTE standardized to 150 mg of EGCG b.i.d. vs placebo over 3 years was conducted to prevent colorectal adenomas (n = 1,001 with colon adenomas enrolled, 40 German centers). Randomization (1:1, n = 879) was performed after a 4-week run-in with GTE for safety assessment. The primary end point was the presence of adenoma/colorectal cancer at the follow-up colonoscopy 3 years after randomization.

Results: The safety profile of GTE was favorable with no major differences in adverse events between the 2 well-balanced groups. Adenoma rate in the modified intention-to-treat set (all randomized participants [intention-to-treat population] and a follow-up colonoscopy 26-44 months after randomization; n = 632) was 55.7% in the placebo and 51.1% in the GTE groups. This 4.6% difference was not statistically significant (adjusted relative risk 0.905; P = 0.1613). The respective figures for the per-protocol population were 54.3% (151/278) in the placebo group and 48.3% (129/267) in the GTE group, indicating a slightly lower adenoma rate in the GTE group, which was not significant (adjusted relative risk 0.883; P = 0.1169).

Discussion: GTE was well tolerated, but there was no statistically significant difference in the adenoma rate between the GTE and the placebo groups in the whole study population.

Trial registration: ClinicalTrials.gov NCT01360320.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992;326:658–62.
    1. Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012;366:687–96.
    1. Winawer SJ, Zauber AG, O'Brien MJ, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 1993;328:901–6.
    1. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885–95.
    1. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674–82.
    1. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873–84.
    1. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891–9.
    1. Drazen JM. COX-2 inhibitors—A lesson in unexpected problems. N Engl J Med 2005;352:1131–2.
    1. Zell JA, Pelot D, Chen WP, et al. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res 2009;2:209–12.
    1. Higurashi T, Hosono K, Takahashi H, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: A multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol 2016;17:475–83.
    1. Whitlock EP, Williams SB, Burda BU, et al. Aspirin use in adults: Cancer, all-cause mortality, and harms. A systematic evidence review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 132. AHRQ Publication No. 13-05193-EF-1 2015.
    1. Balentine DA, Wiseman SA, Bouwens LC. The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 1997;37:693–704.
    1. Johnson R, Bryant S, Huntley AL. Green tea and green tea catechin extracts: An overview of the clinical evidence. Maturitas 2012;73:280–7.
    1. Yuan JM. Cancer prevention by green tea: Evidence from epidemiologic studies. Am J Clin Nutr 2013;98:1676S–1681S.
    1. Kanwar J, Taskeen M, Mohammad I, et al. Recent advances on tea polyphenols. Front Biosci (Elite Ed) 2012;4:111–31.
    1. Rahmani AH, Al Shabrmi FM, Allemailem KS, et al. Implications of green tea and its constituents in the prevention of cancer via the modulation of cell signalling pathway. Biomed Res Int 2015;2015:925640.
    1. Khan N, Afaq F, Saleem M, et al. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 2006;66:2500–5.
    1. Ju J, Hong J, Zhou JN, et al. Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res 2005;65:10623–31.
    1. Sun CL, Yuan JM, Koh WP, et al. Green tea, black tea and colorectal cancer risk: A meta-analysis of epidemiologic studies. Carcinogenesis 2006;27:1301–9.
    1. Wang ZH, Gao QY, Fang JY. Green tea and incidence of colorectal cancer: Evidence from prospective cohort studies. Nutr Cancer 2012;64:1143–52.
    1. Chen Y, Wu Y, Du M, et al. An inverse association between tea consumption and colorectal cancer risk. Oncotarget 2017;8:37367–76.
    1. Shimizu M, Fukutomi Y, Ninomiya M, et al. Green tea extracts for the prevention of metachronous colorectal adenomas: A pilot study. Cancer Epidemiol Biomarkers Prev 2008;17:3020–5.
    1. Shin CM, Lee DH, Seo AY, et al. Green tea extracts for the prevention of metachronous colorectal polyps among patients who underwent endoscopic removal of colorectal adenomas: A randomized clinical trial. Clin Nutr 2018;37:452–8.
    1. Yang G, Zheng W, Xiang YB, et al. Green tea consumption and colorectal cancer risk: A report from the Shanghai Men's Health Study. Carcinogenesis 2011;32:1684–8.
    1. Stingl JC, Ettrich T, Muche R, et al. Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): A randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population. BMC Cancer 2011;11:360.
    1. Greenland S. Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol 2004;160:301–5.
    1. Hull MA, Sprange K, Hepburn T, et al. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): A multicentre, randomised, double-blind, placebo-controlled, 2 x 2 factorial trial. Lancet 2018;392:2583–94.
    1. Hao X, Sun Y, Yang CS, et al. Inhibition of intestinal tumorigenesis in Apc(min/+) mice by green tea polyphenols (polyphenon E) and individual catechins. Nutr Cancer 2007;59:62–9.
    1. Loe DW, Almquist KC, Cole SP, et al. ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J Biol Chem 1996;271:9683–9.
    1. Vaidyanathan JB, Walle T. Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res 2001;18:1420–5.
    1. Scholl C, Lepper A, Lehr T, et al. Population nutrikinetics of green tea extract. PLoS One 2018;13:e0193074.
    1. Xu H, Wang Y, Yuan Y, et al. Gender differences in the protective effects of green tea against amnestic mild cognitive impairment in the elderly Han population. Neuropsychiatr Dis Treat 2018;14:1795–801.
    1. EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS), Younes M, Aggett P, et al. Scientific opinion on the safety of green tea catechins. EFSA J 2018;16:e05239.
    1. Meshitsuka S, Shingaki S, Hotta M, et al. Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis. Int J Hematol 2017;105:295–308.

Referenties meta-analyse studie

References

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.

    Article PubMed Google Scholar 

  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article PubMed Google Scholar 

  3. Brody H. Colorectal cancer. Nature. 2015;521(7551):S1.

    Article CAS PubMed Google Scholar 

  4. Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, Berry DA. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013;24(6):1207–22.

    Article PubMed PubMed Central Google Scholar 

  5. Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology. 2015;148(6):1244-1260.e1216.

    Article CAS PubMed Google Scholar 

  6. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.

    Article PubMed Google Scholar 

  7. Chen Y, Wu Y, Du M, Chu H, Zhu L, Tong N, Zhang Z, Wang M, Gu D, Chen J. An inverse association between tea consumption and colorectal cancer risk. Oncotarget. 2017;8(23):37367–76.

    Article PubMed PubMed Central Google Scholar 

  8. Green CJ, de Dauwe P, Boyle T, Tabatabaei SM, Fritschi L, Heyworth JS. Tea, coffee, and milk consumption and colorectal cancer risk. J Epidemiol. 2014;24(2):146–53.

    Article PubMed PubMed Central Google Scholar 

  9. Luo KW, Xia J, Cheng BH, Gao HC, Fu LW, Luo XL. Tea polyphenol EGCG inhibited colorectal-cancer-cell proliferation and migration via downregulation of STAT3. Gastroenterol Rep (Oxf). 2021;9(1):59–70.

    Article CAS PubMed Google Scholar 

  10. Jin H, Tan X, Liu X, Ding Y. The study of effect of tea polyphenols on microsatellite instability colorectal cancer and its molecular mechanism. Int J Colorectal Dis. 2010;25(12):1407–15.

    Article PubMed Google Scholar 

  11. Michels KB, Willett WC, Fuchs CS, Giovannucci E. Coffee, tea, and caffeine consumption and incidence of colon and rectal cancer. J Natl Cancer Inst. 2005;97(4):282–92.

    Article CAS PubMed Google Scholar 

  12. Suzuki Y, Tsubono Y, Nakaya N, Koizumi Y, Suzuki Y, Shibuya D, Tsuji I. Green tea and the risk of colorectal cancer: pooled analysis of two prospective studies in Japan. J Epidemiol. 2005;15(4):118–24.

    Article PubMed PubMed Central Google Scholar 

  13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed). 2009;339:b2700.

    Article PubMed Google Scholar 

  14. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.

    Article PubMed Google Scholar 

  15. Banke-Thomas AO, Madaj B, Charles A, van den Broek N. Social Return on Investment (SROI) methodology to account for value for money of public health interventions: a systematic review. BMC Public Health. 2015;15:582.

    Article PubMed PubMed Central Google Scholar 

  16. Gosselin V, Boccanfuso D, Laberge S. Social return on investment (SROI) method to evaluate physical activity and sport interventions: a systematic review. Int J Behav Nutr Phys Act. 2020;17(1):26.

    Article PubMed PubMed Central Google Scholar 

  17. Winkley K, Upsher R, Stahl D, Pollard D, Kasera A, Brennan A, Heller S, Ismail K. Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review. Health Technol Assess. 2020;24(28):1–232.

    Article PubMed PubMed Central Google Scholar 

  18. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315(7121):1533–7.

    Article CAS PubMed PubMed Central Google Scholar 

  19. Cerhan JR, Putnam SD, Bianchi GD, Parker AS, Lynch CF, Cantor KP. Tea consumption and risk of cancer of the colon and rectum. Nutr Cancer. 2001;41(1–2):33–40.

    Article CAS PubMed Google Scholar 

  20. Dik VK, Bueno-de-Mesquita HB, Van Oijen MG, Siersema PD, Uiterwaal CS, Van Gils CH, Van Duijnhoven FJ, Cauchi S, Yengo L, Froguel P, et al. Coffee and tea consumption, genotype-based CYP1A2 and NAT2 activity and colorectal cancer risk-results from the EPIC cohort study. Int J Cancer. 2014;135(2):401–12.

    Article CAS PubMed Google Scholar 

  21. Dominianni C, Huang WY, Berndt S, Hayes RB, Ahn J. Prospective study of the relationship between coffee and tea with colorectal cancer risk: the PLCO Cancer Screening Trial. Br J Cancer. 2013;109(5):1352–9.

    Article CAS PubMed PubMed Central Google Scholar 

  22. Hartman TJ, Tangrea JA, Pietinen P, Malila N, Virtanen M, Taylor PR, Albanes D. Tea and coffee consumption and risk of colon and rectal cancer in middle-aged Finnish men. Nutr Cancer. 1998;31(1):41–8.

    Article CAS PubMed Google Scholar 

  23. Heilbrun LK, Nomura A, Stemmermann GN. Black tea consumption and cancer risk: a prospective study. Br J Cancer. 1986;54(4):677–83.

    Article CAS PubMed PubMed Central Google Scholar 

  24. Li X, Yu C, Guo Y, Bian Z, Shen Z, Yang L, Chen Y, Wei Y, Zhang H, Qiu Z, et al. Association between tea consumption and risk of cancer: a prospective cohort study of 0.5 million Chinese adults. Eur J Epidemiol. 2019;34(8):753–63.

    Article CAS PubMed PubMed Central Google Scholar 

  25. Nechuta S, Shu XO, Li HL, Yang G, Ji BT, Xiang YB, Cai H, Chow WH, Gao YT, Zheng W. Prospective cohort study of tea consumption and risk of digestive system cancers: results from the Shanghai Women’s Health Study. Am J Clin Nutr. 2012;96(5):1056–63.

  26. Sinha R, Cross AJ, Daniel CR, Graubard BI, Wu JW, Hollenbeck AR, Gunter MJ, Park Y, Freedman ND. Caffeinated and decaffeinated coffee and tea intakes and risk of colorectal cancer in a large prospective study. Am J Clin Nutr. 2012;96(2):374–81.

    Article CAS PubMed PubMed Central Google Scholar 

  27. Su LJ, Arab L. Tea consumption and the reduced risk of colon cancer – results from a national prospective cohort study. Public Health Nutr. 2002;5(3):419–25.

    Article PubMed Google Scholar 

  28. Sun CL, Yuan JM, Koh WP, Lee HP, Yu MC. Green tea and black tea consumption in relation to colorectal cancer risk: the Singapore Chinese Health Study. Carcinogenesis. 2007;28(10):2143–8.

    Article CAS PubMed Google Scholar 

  29. Tavani A, Pregnolato A, La Vecchia C, Negri E, Talamini R, Franceschi S. Coffee and tea intake and risk of cancers of the colon and rectum: a study of 3,530 cases and 7,057 controls. Int J Cancer. 1997;73(2):193–7.

    Article CAS PubMed Google Scholar 

  30. Yang G, Shu XO, Li H, Chow WH, Ji BT, Zhang X, Gao YT, Zheng W. Prospective cohort study of green tea consumption and colorectal cancer risk in women. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1219–23.

    Article CAS PubMed Google Scholar 

  31. Yang G, Zheng W, Xiang YB, Gao J, Li HL, Zhang X, Gao YT, Shu XO. Green tea consumption and colorectal cancer risk: a report from the Shanghai Men’s Health Study. Carcinogenesis. 2011;32(11):1684–8.

  32. Thomas R, Greef B, McConnachie A, Stanley B, Williams M. Dietary consumption of tea and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Br J Nutr. 2022;128(4):653–8. https://doi.org/10.1017/S0007114521003664.

  33. Jia X, Han C. Effects of green tea on colonic aberrant crypt foci and proliferative indexes in rats. Nutr Cancer. 2001;39(2):239–43.

    Article CAS PubMed Google Scholar 

  34. Pedro DF, Ramos AA, Lima CF, Baltazar F, Pereira-Wilson C. Colon Cancer Chemoprevention by Sage Tea Drinking: Decreased DNA Damage and Cell Proliferation. Phytother Res. 2016;30(2):298–305.

    Article CAS PubMed Google Scholar 

  35. Lee KJ, Inoue M, Otani T, Iwasaki M, Sasazuki S, Tsugane S. Coffee consumption and risk of colorectal cancer in a population-based prospective cohort of Japanese men and women. Int J Cancer. 2007;121(6):1312–8.

    Article CAS PubMed Google Scholar 

  36. Wada K, Oba S, Tsuji M, Goto Y, Mizuta F, Koda S, Uji T, Hori A, Tanabashi S, Matsushita S, et al. Green tea intake and colorectal cancer risk in Japan: the Takayama study. Jpn J Clin Oncol. 2019;49(6):515–20.

    Article PubMed Google Scholar 

  37. Zhang X, Albanes D, Beeson WL, van den Brandt PA, Buring JE, Flood A, Freudenheim JL, Giovannucci EL, Goldbohm RA, Jaceldo-Siegl K, et al. Risk of colon cancer and coffee, tea, and sugar-sweetened soft drink intake: pooled analysis of prospective cohort studies. J Natl Cancer Inst. 2010;102(11):771–83.

    Article CAS PubMed PubMed Central Google Scholar 

  38. Wang XJ, Zeng XT, Duan XL, Zeng HC, Shen R, Zhou P. Association between green tea and colorectal cancer risk: a meta-analysis of 13 case-control studies. Asian Pac J Cancer Prev. 2012;13(7):3123–7.

    Article PubMed Google Scholar 

  39. Wang ZH, Gao QY, Fang JY. Green tea and incidence of colorectal cancer: evidence from prospective cohort studies. Nutr Cancer. 2012;64(8):1143–52.

    Article CAS PubMed Google Scholar 

  40. Yu F, Jin Z, Jiang H, Xiang C, Tang J, Li T, He J. Tea consumption and the risk of five major cancers: a dose-response meta-analysis of prospective studies. BMC Cancer. 2014;14:197.

    Article PubMed PubMed Central Google Scholar 

  41. Zhu MZ, Lu DM, Ouyang J, Zhou F, Huang PF, Gu BZ, Tang JW, Shen F, Li JF, Li YL, et al. Tea consumption and colorectal cancer risk: a meta-analysis of prospective cohort studies. Eur J Nutr. 2020;59(8):3603–15.

    Article PubMed Google Scholar 

  42. Kim TL, Jeong GH, Yang JW, Lee KH, Kronbichler A, van der Vliet HJ, Grosso G, Galvano F, Aune D, Kim JY, et al. Tea consumption and risk of cancer: an umbrella review and meta-analysis of observational studies. Adv Nutr. 2020;11(6):1437–52.

    Article PubMed PubMed Central Google Scholar 

  43. Hu Y, McIntosh GH, Le Leu RK, Somashekar R, Meng XQ, Gopalsamy G, Bambaca L, McKinnon RA, Young GP. Supplementation with Brazil nuts and green tea extract regulates targeted biomarkers related to colorectal cancer risk in humans. Br J Nutr. 2016;116(11):1901–11.

    Article CAS PubMed Google Scholar 

  44. Morris J, Moseley VR, Cabang AB, Coleman K, Wei W, Garrett-Mayer E, Wargovich MJ. Reduction in promotor methylation utilizing EGCG (epigallocatechin-3-gallate) restores RXRα expression in human colon cancer cells. Oncotarget. 2016;7(23):35313–26.

    Article PubMed PubMed Central Google Scholar 

  45. Peluso I, Serafini M. Antioxidants from black and green tea: from dietary modulation of oxidative stress to pharmacological mechanisms. Br J Pharmacol. 2017;174(11):1195–208.

    Article CAS PubMed Google Scholar 

  46. Yuan X, Long Y, Ji Z, Gao J, Fu T, Yan M, Zhang L, Su H, Zhang W, Wen X, et al. Green Tea Liquid Consumption Alters the Human Intestinal and Oral Microbiome. Mol Nutr Food Res. 2018;62(12):e1800178.

    Article PubMed Google Scholar 

  47. Hao X, Xiao H, Ju J, Lee MJ, Lambert JD, Yang CS. Green tea polyphenols inhibit colorectal tumorigenesis in azoxymethane-treated F344 rats. Nutr Cancer. 2017;69(4):623–31.

    Article CAS PubMed Google Scholar 

  48. Ward RE, Benninghoff AD, Healy BJ, Li M, Vagu B, Hintze KJ. Consumption of the total Western diet differentially affects the response to green tea in rodent models of chronic disease compared to the AIN93G diet. Mol Nutr Food Res. 2017;61(4). https://doi.org/10.1002/mnfr.201600720.

  49. Wang ST, Cui WQ, Pan D, Jiang M, Chang B, Sang LX. Tea polyphenols and their chemopreventive and therapeutic effects on colorectal cancer. World J Gastroenterol. 2020;26(6):562–97.

    Article CAS PubMed PubMed Central Google Scholar 

Download references

Acknowledgements

We would like to thank the researchers and study participants for their contributions.

Funding

This work was supported by Hebei Provincial Natural Science Foundation precision medicine joint project (H2020206485) and Hebei Provincial Department of science and technology key project (206Z7705G).

Author information

Author notes

  1. Yu Huang and Qiang Chen contributed equally to this work and share first authorship.

Authors and Affiliations

  1. Department of Gastrointestinal Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, 050051, P.R. China

    Yu Huang, Qiang Chen, Yating Liu, Xu Yin, Yaoguang Hao, Yang Yang, Suyang Yu, Hongyan Li & Guiying Wang

  2. Department of Clinical Medical College, Tianjin Medical University, Tianjin, P.R. China

    Ruoxi Tian

  3. Department of Thoracic Surgery Gastrointestinal Surgery, the Third Hospital of Hebei Medical University, Shijiazhuang, P.R. China

    Jian Yang

  4. Department of Vascular Surgery Gastrointestinal Surgery, the Third Hospital of Hebei Medical University, Shijiazhuang, P.R. China

    Zongxuan Li

Contributions

Yu Huang, Hongyan Li, Suyang Yu and Guiying Wang contributed to conception and design of the study. Qiang Chen, Yating Liu, Ruoxi Tian, Xu Yin, Yaoguang Hao, Yang Yang acquired and analyzed the data. Yating Liu and Yu Huang drafted and revised a significant portion of the manuscript or figures. Zongxuan Li, Xu Yin and Jian Yang conducted the statistical analysis. Yu Huang, Qiang Chen, Yating Liu and Xu Yin wrote the paper. All authors read and approved the present version of manuscript to be published.

Corresponding authors

Correspondence to Suyang Yu, Hongyan Li or Guiying Wang.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

preventie, endeldarmkanker, darmkanker, rectumkanker, thee, groene thee, epigallocatechinengalleaat (EGCG), kwaadaardige darmpoliepen


Plaats een reactie ...

Reageer op "Dagelijks enkele koppen thee vooral groene thee vermindert kans op ontwikkelen van vormen van darmkanker maar is overall niet statistisch significant blijkt uit meta-analyse"


Gerelateerde artikelen
 

Gerelateerde artikelen

Groene thee (EGCG) stopt groei >> Dagelijks enkele koppen thee >> Groene thee en in het bijzonder >> Groene thee extract - epigallocatechin-3-gallate >> Groene thee extract - epigallocatechin >> Wat is groene thee en de werking >> Groene thee extract stimuleert >> Groene thee vermindert kans >> Thee - flavonoiden - en vooral >> Baarmoederhalskanker: Groene >>